Synthesis and in vitro cytotoxicity of cis-dichloro[(2S,3R,4S)-2-aminomethyl-3,4-(O-isopropylidene)dihydroxy- or -3,4-dihydroxypyrrolidine]platinum(II)

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 6, 1996, Pages 643-646

  Kim, Dae Kee ^a   Kim, Young Woo ^a   Kim, Hun Taek ^a   Kim, Key H ^a  

^a Sunkyong Industries   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; PLATINUM 2 AMINOMETHYL 3,4 (O ISOPROPYLIDENE)DIHYDROXYPYRROLIDINE DICHLORIDE; PLATINUM 2 AMINOMETHYL 3,4 DIHYDROXYPYRROLIDINE DICHLORIDE; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA L 1210; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANIMALIA; MURINAE;

EID: 0029932154     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00088-1     Document Type: Article

References (28)

1. Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Nature 1969, 222, 385.
2. (a) Carter, S. K. Platinum Coordination Complexes in Cancer Chemotherapy; Hacker, M. P., Douple, E. B., Krakoff, I. H., Eds.; Martinus Nijhoff Publishing: Boston, 1984; pp. 359;
3. (b) Durant, J. R. Cisplatin Current Status and New Developments; Prestayko, A. W., Crooke, S. T., Carter, S. K., Eds.; Academic Press, Inc.: New York, 1980; pp. 317;
4. (c) Loehrer, P. J.; Einhorn, L. H. Ann. Intern. Med. 1984, 100, 704;
5. (d) Einhorn, L. H.; Donohue, J. Ann. Intern. Med. 1977, 87, 293;
6. (e) Ozols, R. F.; Young, R. C. Semin. Oncol. 1984, 11, 251;
7. (f) Soloway, M. S. J. Urol. 1978, 120, 716.
8. von Hoff, D. D.; Schilsky, R.; Reichert, C. M.; Reddick, R. L.; Rozencweig, M.; Young, R. C.; Muggia, F. M. Cancer Treat. Rep. 1979, 63, 1527.
9. Ozols, R. F. Semin. Oncol. 1985, 12 (Suppl. 4), 7.
10. (a) Carter, S. K.; Canetta, R.; Rozencweig, M. Cancer Treat. Rev. 1985, 12 (Suppl. A), 145;
11. (b) Calvert, A. H.; Harland, S. J.; Newell, D. R.; Siddik, Z. H.; Jones, A. C.; McElwain, T. J.; Raju, S.; Wiltshaw, E.; Smith, I.E.; Baker, J. M.; Peckham, M. J.; Harrap, K. R. Cancer Chemother. Pharmacol. 1982, 9, 140.
12. (a) Canetta, R.; Rosencweig, M.; Carter, S. K. Cancer Treat. Rev. 1985, 12 (Suppl. A), 125;
13. (b) Gore, M.; Fryatt, I.; Wiltshaw, E.; Dawson, T.; Robinson, B.; Calvert, A. Br. J. Cancer 1989, 60, 767.
14. (a) Kim, D.-K.; Kim, G.; Gam, J.; Cho, Y.-B.; Kim, H.-T.; Tai, J.-H.; Kim, K. H.; Hong, W.-S.; Park, J.-G. J. Med. Chem. 1994, 37, 1471;
15. (b) Kim, D.-K.; Gam, J.; Kim, K. H. Bioorg. Med. Chem. Lett. 1994, 4, 911;
16. (c) Morikawa, K.; Honda, M.; Endoh, K.; Matsumoto, T.; Akamatsu, K.; Mitsui, H.; Koizumi, M. J. Pharm. Sci. 1991, 80, 837;
17. (d) Totani, T.; Aono, K.; Komura, M.; Adachi, Y. Chem. Lett. 1986, 429;
18. (e) Kraker, A. J.; Hoeschele, J. D.; Elliott, W. L.; Showalter, H. D. H.; Sercel, A. D. J. Med. Chem. 1992, 35, 4526;
19. (f) Mellish, K. J.; Kelland, L. R.; Harrap, K. R. Br. J. Cancer 1993, 68, 240.
20. (a) Majima, H. Anti-Cancer Drug Design 1991, 6, 293;
21. (b) Kamisango, K.; Matsumoto, T.; Akamatsu, K.; Morikawa, K.; Koizumi, K.; Tashiro, T. Anti-Cancer Drug Design 1991, 6, 317;
22. (c) Endo, K.; Akamatsu, K.; Matsumoto, T.; Morikawa, K.; Koizumi, M.; Mitsui, H.; Koizumi, K. Anticancer Res. 1992, 12, 49;
23. (d) Kobayashi, H.; Takemura, Y.; Miyachi, H.: Ogawa, T. Invest. New Drug 1991, 9, 313.
24. Nakai, Y. Jpn. J. Cancer Chemother. 1992, 19, 2157.
25. Kim, D.-K.; Kim, G.; Kim, Y.-W. J. Chem. Soc., Perkin Trans, 1 1996, in press.
26. 2Pt: C, 15.08; H, 3.04; N, 7.04. Found: C, 14.82; H, 3.10; N, 6.91.
27. Hudson, L.; Hay, F. C. Practical Immunology; Blackwell Scientific Publications: Oxford, England, 1976, pp. 29.
28. Boyd, M. R. Principles Practices Oncol. 1989, 3, 1.